On September 18, Abbott announced that Instant Sense 2 has been approved by the China Drug Administration's integrated continuous glucose monitoring system, making it the first and currently the only dynamic blood sugar meter in China to receive this certification. Instantaneous Sense 2 was approved in China as early as 2023. It is an auxiliary continuous glucose monitoring system. In other words, product measurement results can only be used by users to track trends in sugar values. They are not used as a basis for adjusting and deciding treatment plans, and data cannot enter the clinical treatment decision-making process. Currently approved according to the new standard, it means that its measurement results can be directly used in treatment support decisions for adult diabetics. Up to now, Instantaneous Sense 2 is also the only domestic continuous glucose monitoring system product that can be used to assist decision-making in adult diabetes treatment.

On September 18, Abbott announced that Instant Sense 2 has been approved by the China Drug Administration's integrated continuous glucose monitoring system, making it the first and currently the only dynamic blood sugar meter in China to receive this certification. Instantaneous Sense 2 was approved in China as early as 2023. It is an auxiliary continuous glucose monitoring system. In other words, product measurement results can only be used by users to track trends in sugar values. They are not used as a basis for adjusting and deciding treatment plans, and data cannot enter the clinical treatment decision-making process. Currently approved according to the new standard, it means that its measurement results can be directly used in treatment support decisions for adult diabetics. Up to now, Instantaneous Sense 2 is also the only domestic continuous glucose monitoring system product that can be used to assist decision-making in adult diabetes treatment.